Addus HomeCare Corporation — Medical Care Facilities. Scored on the same transparent 7-signal model behind the daily rankings.
★
ADUS
Addus HomeCare Corporation · Medical Care Facilities
FCF$137mC
Rev+23.2%A-
D/E0.12B+
P/E19.7xA-
PEG1.02B+
76.6Score
$109.72$2.0B
1Y Target$132.69Analyst consensus · 13 analysts
5Y Target$194.27Compound horizon
10Y Target$288.19Long-dated conviction
FCF$137mTTMC
FCF $137m — modest; watch for margin expansion
Rev+23.2%TTM YoYA-
Revenue +23.2% — strong growth, well above S&P median (~7%)
D/E0.12B+
D/E 0.12 — below the Healthcare debt median (≈40th pctile)
P/E19.7xA-
P/E 19.7 — cheaper than most Healthcare peers (≈25th pctile)
PEG1.02B+
PEG 1.02 — near fair value, classic Lynch benchmark (1.0)
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 76.6
Quality0.57
Growth0.96
Value0.82
Entry · Margin of safety
52-week rangeMid-range
12% off the 12-month high
vs DCF fair value16% belowest. fair value ~$131
Quality signals · context only
Gross profitability33% · B+gross profit ÷ total assets (Novy-Marx)
ROIC9.3% · Breturn on invested capital — not score-weighted
Why now
Medical Care Facilities · market cap $2.0b. 12% off the 52-week high of $124.44. Revenue growing +23%, comfortably above the S&P median. 13 sell-side analysts rate this a Buy with a mean 1-yr target of $132.69 (implying +21% upside).
Moat
FCF converts 138% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Horizon
1-3 yr $132.69 (13-analyst consensus) — fundamentals + valuation re-rating. 5 yr $194.27 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $288.19 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Position sizing · ADUS
$
%
%
Shares to buy
18
Position size
$1,975
3.9% of portfolio
Stop price
$82.29
25% below $109.72
$ at risk if stopped
$493.74
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Addus HomeCare Corporation (ADUS) is a Medical Care Facilities company that scores 76.6 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are Rev (A-), P/E (A-) and D/E (B+). On valuation, ADUS sits about 16% below our discounted-cash-flow fair value (a margin of safety).
Is ADUS a good stock to buy?
Bull Rankings scores ADUS 76.6 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by Rev (A-), P/E (A-) and D/E (B+). A score is a quantitative screen of Addus HomeCare Corporation's fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does ADUS score 76.6 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). ADUS earns its highest marks on Rev (A-), P/E (A-) and D/E (B+). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is ADUS overvalued or undervalued?
Based on $109.72, ADUS sits about 16% below our discounted-cash-flow fair value (a margin of safety). It trades at a 19.7x× P/E (graded A-). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in ADUS?
Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.